GlassScriptPhysician profile
Frank T Dean
NPI 1316947666
$418.03
in general payments reported to CMS, 2019-2025
16 companies · $16.07 in 2025
The $16.07 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $65.27 · 2022: $146 · 2023: $21.68 · 2024: $52.43 · 2025: $16.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $90.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $90.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $51.30 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $43.80 | 2019-2020 | |
| Organon LLC | $41.15 | 2022-2023 | Nexplanon |
| Allergan, INC. | $31.47 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $29.12 | 2022 | |
| Amag Pharmaceuticals, INC. | $28.15 | 2019-2020 | |
| Abbvie INC. | $24.15 | 2022 | |
| Shield Therapeutics INC | $23.52 | 2022 | |
| Hologic Sales and Service, LLC | $21.55 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.66 | 2019 | |
| Exeltis, USA INC. | $18.80 | 2019 | |
| Myovant Sciences INC. | $18.33 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $17.20 | 2024 | Caldolor |
| Mission Pharmacal Company | $17.14 | 2020 | |
| Therapeuticsmd, INC. | $16.24 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $15.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.